Aktis Oncology, Inc. Common stock (AKTS) — Cash Flow Reinvestment Rate

Latest as of December 2024: 12.90x

Aktis Oncology, Inc. Common stock (AKTS) has a Cash Flow Reinvestment Rate of 12.90x as of December 2024, reinvesting $190.40 Million (capex $2.86 Million plus investments $-187.54 Million) from operating cash flow of $14.76 Million. Explore Aktis Oncology, Inc. Common stock (AKTS) capital reinvestment to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

12.90x
(Capex + Investments) / Operating CF

Total Reinvested

$190.40 Million
Capex + Investments

Operating Cash Flow

$14.76 Million
USD

Capital Expenditures

$2.86 Million
USD

Aktis Oncology, Inc. Common stock Cash Flow Reinvestment Rate (2024–2024)

Historical reinvestment intensity for Aktis Oncology, Inc. Common stock across 1 annual periods. Also explore AKTS total asset value for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Aktis Oncology, Inc. Common stock (2024–2024)

Year-by-year capital reinvestment analysis for Aktis Oncology, Inc. Common stock. For live market cap and broader valuation context, see Aktis Oncology, Inc. Common stock market cap and net worth.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2024 12.90x $190.40 Million $14.76 Million $2.86 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow